132 related articles for article (PubMed ID: 34155340)
1. Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
Sjoberg HT; Philippou Y; Magnussen AL; Tullis IDC; Bridges E; Chatrian A; Lefebvre J; Tam KH; Murphy EA; Rittscher J; Preise D; Agemy L; Yechezkel T; Smart SC; Kinchesh P; Gilchrist S; Allen DP; Scheiblin DA; Lockett SJ; Wink DA; Lamb AD; Mills IG; Harris A; Muschel RJ; Vojnovic B; Scherz A; Hamdy FC; Bryant RJ
Br J Cancer; 2021 Aug; 125(4):534-546. PubMed ID: 34155340
[TBL] [Abstract][Full Text] [Related]
2. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
3. Vascular-targeted Photodynamic Therapy in Unilateral Low-risk Prostate Cancer in Germany: 2-yr Single-centre Experience in a Real-world Setting Compared with Radical Prostatectomy.
Flegar L; Buerk B; Proschmann R; Propping S; Groeben C; Baunacke M; Herout R; Huber J; Thomas C; Borkowetz A
Eur Urol Focus; 2022 Jan; 8(1):121-127. PubMed ID: 33602642
[TBL] [Abstract][Full Text] [Related]
4. Bombesin Antagonist-Based Radiotherapy of Prostate Cancer Combined with WST-11 Vascular Targeted Photodynamic Therapy.
Kim K; Zhang H; La Rosa S; Jebiwott S; Desai P; Kimm S; Scherz A; O'Donoghue JA; Weber WA; Coleman JA
Clin Cancer Res; 2017 Jul; 23(13):3343-3351. PubMed ID: 28108545
[No Abstract] [Full Text] [Related]
5. TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.
Azzouzi AR; Barret E; Moore CM; Villers A; Allen C; Scherz A; Muir G; de Wildt M; Barber NJ; Lebdai S; Emberton M
BJU Int; 2013 Oct; 112(6):766-74. PubMed ID: 24028764
[TBL] [Abstract][Full Text] [Related]
6. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).
Noweski A; Roosen A; Lebdai S; Barret E; Emberton M; Benzaghou F; Apfelbeck M; Gaillac B; Gratzke C; Stief C; Azzouzi AR
Eur Urol Focus; 2019 Nov; 5(6):1022-1028. PubMed ID: 29661587
[TBL] [Abstract][Full Text] [Related]
7. Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.
Madar-Balakirski N; Tempel-Brami C; Kalchenko V; Brenner O; Varon D; Scherz A; Salomon Y
PLoS One; 2010 Apr; 5(4):e10282. PubMed ID: 20421983
[TBL] [Abstract][Full Text] [Related]
8. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model.
Philippou Y; Sjoberg HT; Murphy E; Alyacoubi S; Jones KI; Gordon-Weeks AN; Phyu S; Parkes EE; Gillies McKenna W; Lamb AD; Gileadi U; Cerundolo V; Scheiblin DA; Lockett SJ; Wink DA; Mills IG; Hamdy FC; Muschel RJ; Bryant RJ
Br J Cancer; 2020 Sep; 123(7):1089-1100. PubMed ID: 32641865
[TBL] [Abstract][Full Text] [Related]
9. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors.
O'Shaughnessy MJ; Murray KS; La Rosa SP; Budhu S; Merghoub T; Somma A; Monette S; Kim K; Corradi RB; Scherz A; Coleman JA
Clin Cancer Res; 2018 Feb; 24(3):592-599. PubMed ID: 28954788
[No Abstract] [Full Text] [Related]
10. Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.
Moore CM; Azzouzi AR; Barret E; Villers A; Muir GH; Barber NJ; Bott S; Trachtenberg J; Arumainayagam N; Gaillac B; Allen C; Schertz A; Emberton M
BJU Int; 2015 Dec; 116(6):888-96. PubMed ID: 24841929
[TBL] [Abstract][Full Text] [Related]
11. WST11 Vascular Targeted Photodynamic Therapy Effect Monitoring by Multispectral Optoacoustic Tomography (MSOT) in Mice.
Neuschmelting V; Kim K; Malekzadeh-Najafabadi J; Jebiwott S; Prakash J; Scherz A; Coleman JA; Kircher MF; Ntziachristos V
Theranostics; 2018; 8(3):723-734. PubMed ID: 29344301
[No Abstract] [Full Text] [Related]
12. Follow-up of vascular-targeted photodynamic therapy in a real-world setting.
Borkowetz A; Kwe J; Boehm K; Baunacke M; Herout R; Lucke M; Burcea A; Thomas C
World J Urol; 2024 Jan; 42(1):55. PubMed ID: 38244089
[TBL] [Abstract][Full Text] [Related]
13. [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
Kleinclauss F; Frontczak A; Balssa L; Lebdai S; Azzouzi R
Prog Urol; 2019; 29(8-9):393-401. PubMed ID: 31266699
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions.
Røe K; Seierstad T; Kristian A; Mikalsen LT; Mælandsmo GM; van der Kogel AJ; Ree AH; Olsen DR
Neoplasia; 2010 Oct; 12(10):818-25. PubMed ID: 20927320
[TBL] [Abstract][Full Text] [Related]
15. Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.
Kawczyk-Krupka A; Wawrzyniec K; Musiol SK; Potempa M; Bugaj AM; Sieroń A
Photodiagnosis Photodyn Ther; 2015 Dec; 12(4):567-74. PubMed ID: 26467273
[TBL] [Abstract][Full Text] [Related]
16. Combined OX40 Agonist and PD-1 Inhibitor Immunotherapy Improves the Efficacy of Vascular Targeted Photodynamic Therapy in a Urothelial Tumor Model.
Alvim RG; Georgala P; Nogueira L; Somma AJ; Nagar K; Thomas J; Alvim L; Riegel A; Hughes C; Chen J; Reis AB; Lebdai S; Scherz A; Zanganeh S; Gardner R; Kim K; Coleman JA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205347
[TBL] [Abstract][Full Text] [Related]
17. Systemic antitumor protection by vascular-targeted photodynamic therapy involves cellular and humoral immunity.
Preise D; Oren R; Glinert I; Kalchenko V; Jung S; Scherz A; Salomon Y
Cancer Immunol Immunother; 2009 Jan; 58(1):71-84. PubMed ID: 18488222
[TBL] [Abstract][Full Text] [Related]
18. Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP).
Preise D; Scherz A; Salomon Y
Photochem Photobiol Sci; 2011 May; 10(5):681-8. PubMed ID: 21258718
[TBL] [Abstract][Full Text] [Related]
19. Erectile function after WST11 vascular-targeted photodynamic therapy for low-risk prostate cancer treatment.
Chelly S; Maulaz P; Bigot P; Azzouzi AR; Lebdai S
Asian J Androl; 2020; 22(5):454-458. PubMed ID: 31939351
[TBL] [Abstract][Full Text] [Related]
20. Which technology to select for primary focal treatment of prostate cancer?-European Section of Urotechnology (ESUT) position statement.
Ganzer R; Arthanareeswaran VKA; Ahmed HU; Cestari A; Rischmann P; Salomon G; Teber D; Liatsikos E; Stolzenburg JU; Barret E
Prostate Cancer Prostatic Dis; 2018 Jun; 21(2):175-186. PubMed ID: 29743538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]